T2DM

CompletedPhase 1

Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of NA-931 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus

Lead sponsor

Biomed Industries, Inc.

Asset

NA-931

Oral · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI 25-40

Primary endpoint

•Treatment-Emergent Adverse Events in NA-931 participants

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06615700

Org study IDNA-931-50

Timeline

Milestones

Study start2024-05-06actual

Primary completion2024-08-12actual

Study completion2024-09-20actual

Study first posted2024-09-27actual

Last update posted2024-09-27actual

Assets

Investigational agents

NA-931

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Participants 18-65 years old, inclusive

•BMI of 25 - 40, inclusive

•Stable body weight for two months

•Participants must be capable of giving signed informed consent

•Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical study procedures

•Willing to comply with contraception requirements

Exclusion criteria

•History of significant medical conditions and malignancy

•Uncontrollable hypertension

•History of alcoholism or drug addiction within 1 year prior to Screening

•Current or recent participation in an investigational clinical trial

•Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

3 endpoints

Primary/protocol endpoint

Incidence of Treatment-Emergent Adverse Events in NA-931 participants

Time frame:28 days

event count, event

Secondary/protocol endpoint

Maximum observe drug concentration (Cmax) of NA-931

Time frame:28 days

concentration, descriptive

Secondary/protocol endpoint

Effect of a High-Fat Meal on Plasma Concentration of NA-931

Time frame:28 days

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.